Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date

• DOI: 10.1007/s40272-023-00606-6
• Publication Date: 2023-11-30T11:02:23Z
• Authors: Charl Verwey; Ziyaad Dangor; Shabir A. Madhi
• Keywords: Palivizumab; Licensure

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay RSV management supportive therapy such as supplemental oxygen. Palivizumab (Synagis™–AstraZeneca), a monoclonal antibody targeting F protein site II, has been licensed prevention high-risk groups since 1998. There recent promising progress preventative strategies that include vaccines long-acting, high-potency antibodies. Nirsevimab (Beyfortus™–AstraZeneca/Sanofi), an extended half-life, recently registered European Union granted licensure by US Food Drug Administration. Furthermore, pre-fusion sub-unit vaccine pregnant women, aimed at protecting their young infants, following established safety efficacy clinical trials (Abrysvo™–Pfizer). Also, multiple novel antiviral therapeutic options are early phase trials. next few have potential change landscape LRTI through improvements LRTI. Here, we discuss these new approaches, current research, therapeutics, antibodies, against infants children.